ReShape Lifesciences announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study ...
ReShape Lifesciences Inc. announced today that the Company will be presenting early results of a new, novel use of the ReShape Lifesciences™ neuro-blocking technology in combination with separate-site vagus nerve stimulation for the treatment of type 2